Skip to main content
Top
Published in: CardioVascular and Interventional Radiology 4/2019

01-04-2019 | Clinical Investigation

Phase II Trial of Transarterial Embolization Using an n-Butyl-2-Cyanoacrylate/Lipiodol Mixture (JIVROSG-0802)

Authors: Shunsuke Sugawara, Yasuaki Arai, Miyuki Sone, Tsuneo Ishiguchi, Akira Kitagawa, Takeshi Aramaki, Rui Sato, Hiroyuki Morishita, Yoshito Takeuchi, Yoshitaka Inaba

Published in: CardioVascular and Interventional Radiology | Issue 4/2019

Login to get access

Abstract

Purpose

To evaluate the embolic effect and the safety of transarterial embolization (TAE) using n-butyl-2-cyanoacrylate (NBCA) in a prospective multicenter trial.

Materials and Methods

This study was an open-label, multicenter, phase II trial. The inclusion criteria were (1) active bleeding or pseudoaneurysm, (2) true aneurysm, (3) arteriovenous malformation (except cerebral lesion), (4) arteriovenous fistula, or (5) need for arterial distribution before transarterial treatment. Selective TAE with NBCA diluted 2–10 times was performed. The primary endpoint was the success rate of embolization with a per-patient analysis based on the angiographic findings. Secondary endpoints were safety, evaluated based on Common Terminology Criteria for Adverse Events (CTCAE) version 4, and the success rate of embolization with a per-vessel calculation.

Results

Sixty-five patients were initially enrolled, but due to protocol violation in two patients, efficacy was ultimately analyzed in 63 patients (103 vessels) and safety was analyzed in 64 patients. The success rate per patient was 98.4% (62/63; 95% confidence interval (CI), 91.5–100.00), and the success rate per vessel was 99.0% (102/103; 95% CI, 94.7–100.0). Adverse events of grade 3 or above based on CTCAE version 4 occurred in 22/64 patients (34.4%). Twelve intraoperative or postoperative adverse events grade 3 or above, which may have been related to embolization using NBCA, occurred in 11/64 patients (17.2%). Three patients died after embolization using NBCA, but their deaths were unrelated to TAE.

Conclusion

In this prospective multicenter clinical trial, the efficacy of TAE using NBCA was 98.4% and adverse events were clinically acceptable.

Level of Evidence

Level 3b.
Appendix
Available only for authorised users
Literature
4.
go back to reference Arai Y. Glue. In: Marcelo Guimaraes RL, Gary P, editors. Embolization Therapy. 1st ed. Alphen aan den Rijn: Wolters Kluwer; 2015. p. 45–50. Arai Y. Glue. In: Marcelo Guimaraes RL, Gary P, editors. Embolization Therapy. 1st ed. Alphen aan den Rijn: Wolters Kluwer; 2015. p. 45–50.
9.
go back to reference n BCATI. N-butyl cyanoacrylate embolization of cerebral arteriovenous malformations: results of a prospective, randomized, multi-center trial. AJNR Am J Neuroradiol. 2002;23(5):748–55. n BCATI. N-butyl cyanoacrylate embolization of cerebral arteriovenous malformations: results of a prospective, randomized, multi-center trial. AJNR Am J Neuroradiol. 2002;23(5):748–55.
11.
go back to reference Inaba Y, Arai Y, Matsueda K, Takeuchi Y, Aramaki T. Right gastric artery embolization to prevent acute gastric mucosal lesions in patients undergoing repeat hepatic arterial infusion chemotherapy. J Vasc Interv Radiol. 2001;12(8):957–63.CrossRefPubMed Inaba Y, Arai Y, Matsueda K, Takeuchi Y, Aramaki T. Right gastric artery embolization to prevent acute gastric mucosal lesions in patients undergoing repeat hepatic arterial infusion chemotherapy. J Vasc Interv Radiol. 2001;12(8):957–63.CrossRefPubMed
22.
go back to reference Winkelbauer FW, Nierderle B, Graf O, Prokesch R, Thurnher S, Wildling R, et al. Malignant insulinoma: permanent hepatic artery embolization of liver metastases–preliminary results. Cardiovasc Intervent Radiol. 1995;18(6):353–9.CrossRefPubMed Winkelbauer FW, Nierderle B, Graf O, Prokesch R, Thurnher S, Wildling R, et al. Malignant insulinoma: permanent hepatic artery embolization of liver metastases–preliminary results. Cardiovasc Intervent Radiol. 1995;18(6):353–9.CrossRefPubMed
28.
go back to reference Song JK, Gobin YP, Duckwiler GR, Murayama Y, Frazee JG, Martin NA, et al. N-butyl 2-cyanoacrylate embolization of spinal dural arteriovenous fistulae. AJNR Am J Neuroradiol. 2001;22(1):40–7.PubMed Song JK, Gobin YP, Duckwiler GR, Murayama Y, Frazee JG, Martin NA, et al. N-butyl 2-cyanoacrylate embolization of spinal dural arteriovenous fistulae. AJNR Am J Neuroradiol. 2001;22(1):40–7.PubMed
31.
go back to reference Bent CL, Low D, Matson MB, Renfrew I, Fotheringham T. Portal vein embolization using a nitinol plug (Amplatzer vascular plug) in combination with histoacryl glue and iodinized oil: adequate hypertrophy with a reduced risk of nontarget embolization. Cardiovasc Intervent Radiol. 2009;32(3):471–7. https://doi.org/10.1007/s00270-009-9515-9.CrossRefPubMed Bent CL, Low D, Matson MB, Renfrew I, Fotheringham T. Portal vein embolization using a nitinol plug (Amplatzer vascular plug) in combination with histoacryl glue and iodinized oil: adequate hypertrophy with a reduced risk of nontarget embolization. Cardiovasc Intervent Radiol. 2009;32(3):471–7. https://​doi.​org/​10.​1007/​s00270-009-9515-9.CrossRefPubMed
Metadata
Title
Phase II Trial of Transarterial Embolization Using an n-Butyl-2-Cyanoacrylate/Lipiodol Mixture (JIVROSG-0802)
Authors
Shunsuke Sugawara
Yasuaki Arai
Miyuki Sone
Tsuneo Ishiguchi
Akira Kitagawa
Takeshi Aramaki
Rui Sato
Hiroyuki Morishita
Yoshito Takeuchi
Yoshitaka Inaba
Publication date
01-04-2019
Publisher
Springer US
Published in
CardioVascular and Interventional Radiology / Issue 4/2019
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-018-2141-7

Other articles of this Issue 4/2019

CardioVascular and Interventional Radiology 4/2019 Go to the issue